World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
155
Citations
135431
World Ranking
931
National Ranking
530

Overview

Toni K. Choueiri is affiliated with Harvard University in the United States. Their research focuses primarily on medicine, with significant contributions in the fields of biochemistry, genetics, and molecular biology. Specific subfields of interest include pulmonary and respiratory medicine, oncology, cancer research, molecular biology, and the economics and econometrics associated with health sciences.

The scientist's work covers a range of topics related to cancer and its treatment, particularly renal cell carcinoma and associated cancers. Other key areas include cancer immunotherapy and biomarkers, cancer genomics and diagnostics, economic and financial impacts of cancer, bladder and urothelial cancer treatments, and pancreatic and hepatic oncology research.

Toni K. Choueiri has coauthored numerous publications with several frequent collaborators. These include:

  • Robert J. Motzer
  • Ziad Bakouny
  • Rana R. McKay
  • David F. McDermott
  • Brian I. Rini

The scientist's research has been published in a variety of venues, with repeated contributions to these journals and publications:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Oncologist
  • European Urology
  • Nature Medicine

Representative recent papers include:

  • "Post-acute COVID-19 syndrome," 2021, Nature Medicine
  • "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study," 2020, The Lancet
  • "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma," 2021, New England Journal of Medicine
  • "Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma," 2021, New England Journal of Medicine
  • "Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma," 2020, Nature Medicine

Best Publications

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • The Immune Landscape of Cancer

    Vésteinn Thorsson;David L Gibbs;Scott D Brown;Denise Wolf

  • Comprehensivemolecular characterization of clear cell renal cell carcinoma

    Chad J. Creighton;Margaret Morgan;Preethi H. Gunaratne;Preethi H. Gunaratne;David A. Wheeler

  • Post-acute COVID-19 syndrome.

    Ani Nalbandian;Kartik Sehgal;Kartik Sehgal;Aakriti Gupta;Aakriti Gupta;Mahesh V Madhavan

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

    W. Marston Linehan;Paul T. Spellman;Christopher J. Ricketts;Chad J. Creighton

  • Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Wenhua Gao;Martin H. Voss;Martin H. Voss

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

    Toni K. Choueiri;Thomas Powles;Mauricio Burotto;Bernard Escudier

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Systemic Therapy for Metastatic Renal-Cell Carcinoma.

    Toni K Choueiri;Robert J Motzer

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Marital Status and Survival in Patients With Cancer

    Ayal A. Aizer;Ming Hui Chen;Ellen P. McCarthy;Mallika L. Mendu

Frequent Co-Authors

Quoc-Dien Trinh
Quoc-Dien Trinh Brigham and Women's Hospital
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Paul L. Nguyen
Paul L. Nguyen Harvard Medical School
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Thomas Powles
Thomas Powles Queen Mary University of London
Michael B. Atkins
Michael B. Atkins Georgetown University
Laurence Albiges
Laurence Albiges Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in a healthcare career, but not sure if medical school is right for you? There are several online degree options that can lead to rewarding roles in medicine and health sciences.

For those considering nursing, enrolling in a nursing school that does not require teas test can make the admissions process more accessible. These schools remove common standardized testing barriers, allowing more students to pursue nursing.

If you’re interested in the business side of healthcare, an accelerated healthcare administration degree online can fast-track your entry into management and administrative roles. These flexible programs cater to busy adults and career changers.

Current registered nurses looking to advance their careers may consider adn to fnp bridge programs. These bridge pathways help nurses build on their existing education and move toward becoming a family nurse practitioner.

There are also great options in public health and wellness. Explore online nutrition degrees for careers in dietetics, health promotion, and food science.

Best Scientists Citing Toni K. Choueiri

Trending Scientists